To confirm that the ability of raltegravir to alleviate LPS-induced endothelial dysfunction was linked to the strengthening of cell-cell junctions, we next measured VE-cadherin and claudin 18.1 expression levels in these HPMECs via western blotting and immunofluorescent (IF) staining. The gene discussed is CDH5; the disease is endothelial dysfunction.